title: Intracoronary adiponectin at reperfusion reduces infarct size in a porcine myocardial infarction model.
abstract: Reperfusion injury (RI) remains an important limitation of myocardial revascularization. The aim of the present study was to evaluate the influence of the intracoronary injection of adiponectin on RI and cardiomyocyte death in a porcine myocardial infarction model. Acute infarction in 14 Polish domestic pigs was induced by inflation of an over the wire balloon (OTW) catheter in the medial left anterior descending artery for 60 min. The study group consisted of 7 pigs in which intracoronary adiponectin (50 µg) was infused through the OTW catheter immediately before reperfusion. The control group (n=7) was administered placebo. Animals were sacrificed after two days of follow-up. The infarct area (IA) was stained with tetrazoline and the area at risk (AAR) with intracoronary administration of Evans Blue dye before euthanasia. Hearts in each group had similar AARs (46.2±9.9% vs. 48.4±6.2% of the whole myocardium, p=ns). The IA/AAR% and IA were smaller in the study group when compared to the control (24.7±4.0% vs. 45.3±22.5%, p=0.005; and 11.7±4.9% vs. 20.5±5.6%, p=0.01, respectively). These outcomes corresponded well with the peak troponin levels after 12 h (109.9±60.9 ng/ml vs. 185.5±39.4 ng/ml, p=0.017). After two days there was a significantly higher LVEF in the study group (51.4±8.5% vs. 33.9±8.6%, p=0.002). There was also a trend toward lower apoptosis enhancement in the viable myocardium in the study group (3.11±2.3 vs. 8.92±6.3; p=0.07). The administration of adiponectin into the infarct- related artery is safe and feasible. The treatment significantly reduced the infarct size.
authors.affiliation: American Heart of Poland, Katowice, Poland. dabbad@wp.pl
authors.forename: Marcin
authors.initials: M
authors.lastname: Dębiński
authors.forename: Piotr P
authors.initials: PP
authors.lastname: Buszman
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Milewski
authors.forename: Wojciech
authors.initials: W
authors.lastname: Wojakowski
authors.forename: Wanda
authors.initials: W
authors.lastname: Jackiewicz
authors.forename: Jacek
authors.initials: J
authors.lastname: Pająk
authors.forename: Dariusz
authors.initials: D
authors.lastname: Szurlej
authors.forename: Joanna
authors.initials: J
authors.lastname: Fryc-Stanek
authors.forename: Szymon
authors.initials: S
authors.lastname: Wiernek
authors.forename: Michal
authors.initials: M
authors.lastname: Jelonek
authors.forename: Michael E
authors.initials: ME
authors.lastname: Spurlock
authors.forename: Jack
authors.initials: J
authors.lastname: Martin
authors.forename: Andrzej
authors.initials: A
authors.lastname: Bochenek
authors.forename: Pawel E
authors.initials: PE
authors.lastname: Buszman
mesh_terms: D052242:Adiponectin / Q000008:administration & dosage* / Q000627:therapeutic use; D000818:Animals; D005260:Female; D008297:Male; D009203:Myocardial Infarction / Q000188:drug therapy*; D015425:Myocardial Reperfusion; D015428:Myocardial Reperfusion Injury / Q000188:drug therapy*; D034421:Sus scrofa; D013997:Time Factors
chemical_list: D052242:Adiponectin